Real‐World Outcomes of Rituximab in Pemphigus: An Australian Tertiary Cohort
Аннотация
ABSTRACT Rituximab is endorsed internationally as first‐line therapy for moderate‐to‐severe pemphigus, but Australian guidelines position it as a rescue agent and local outcome data are limited. In this single‐centre retrospective cohort, 24 adults with pemphigus vulgaris ( n = 16) or pemphigus foliaceus ( n = 8) received rituximab as part of routine care; median follow‐up from first infusion was 24.9 months. Disease control was documented in all patients and complete remission in 20 (83%), of whom half subsequently relapsed despite most receiving more than one cycle. Adverse events occurred in eight patients (33%), predominantly mild infusion‐related reactions, with one fatal pneumonia. These real‐world data support planned maintenance after remission rather than single‐course rescue use, and prospective multicentre study with standardised severity scoring.